RARE Ultragenyx Pharmaceutical Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1515673 · Fiscal year ends 12/31
Financial factors as of 2025-12-31 (2025Q4), TTM = sum of the last four quarters
Growth
TTM revenue YoY20.2%
TTM net income YoY-0.9%
TTM EPS YoY7.3%
Revenue 3-yr CAGR22.8%
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin-79.5%
Net margin-85.3%
FCF margin-70.1%
EBITDA margin-74.3%
Returns
ROE-656.6%
ROA-37.9%
ROIC (approx.)—
Asset turnover0.44x
Leverage & solvency
Liabilities / assets104.8%
Debt / equity—
Current ratio2.48x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.81x
Accruals ratio-7.2%
Payout ratio—
Capex / revenue0.9%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $173.00M | $214.00M | $136.00M | $207.28M | $160.00M | $167.00M | $139.00M | $164.88M |
| R&D expense | $154.00M | $167.00M | $187.00M | $203.28M | $216.00M | $165.00M | $166.00M | $187.77M |
| SG&A expense | $97.00M | $88.00M | $88.00M | $87.94M | $87.00M | $87.00M | $87.00M | $82.50M |
| Operating income | -$110.00M | -$75.00M | -$169.00M | -$113.28M | -$171.00M | -$108.00M | -$143.00M | -$122.28M |
| Pretax income | -$127.00M | -$91.00M | -$184.00M | -$128.00M | -$179.00M | -$114.00M | -$150.00M | -$133.40M |
| Income tax | -$9.00M | $1.00M | $1.00M | $870,000 | $1.00M | $1.00M | $1.00M | -$19,000 |
| Net income | -$118.00M | -$92.00M | -$185.00M | -$128.56M | -$180.00M | -$115.00M | -$151.00M | -$133.38M |
| EBITDA | -$101.00M | -$67.00M | -$161.00M | -$104.50M | -$163.00M | -$99.00M | -$134.00M | -$113.20M |
| EPS (basic) | -1.16 | -0.90 | -1.84 | — | -1.81 | -1.17 | -1.57 | — |
| EPS (diluted) | -1.16 | -0.90 | -1.84 | — | -1.81 | -1.17 | -1.57 | — |
| Weighted avg. shares (diluted) | 102.10M | 101.90M | 100.60M | — | 99.80M | 98.50M | 96.30M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $150.00M | $125.00M | $175.00M | $421.00M | $203.00M | $176.00M | $127.00M | $174.00M |
| Short-term investments | $116.00M | $167.00M | $238.00M | $259.00M | $222.74M | $311.28M | $367.38M | $436.00M |
| Receivables | $166.00M | $200.00M | $121.00M | $158.00M | $112.54M | $124.46M | $98.84M | $122.00M |
| Inventory | $59.00M | $59.00M | $55.00M | $52.00M | $52.20M | $46.50M | $46.03M | $45.00M |
| Current assets | $544.00M | $606.00M | $657.00M | $951.00M | $643.21M | $719.79M | $699.15M | $817.00M |
| PP&E, net | $231.00M | $235.00M | $239.00M | $244.00M | $249.96M | $255.76M | $260.91M | $266.00M |
| Goodwill | $44.00M | $44.00M | $44.00M | $44.00M | $44.41M | $44.41M | $44.41M | $44.00M |
| Intangibles | $170.00M | $172.00M | $174.00M | $176.00M | $172.94M | $174.73M | $176.52M | $178.00M |
| Total assets | $1.19B | $1.26B | $1.30B | $1.53B | $1.19B | $1.31B | $1.31B | $1.50B |
| Current liabilities | $389.00M | $351.00M | $325.00M | $384.00M | $340.02M | $293.24M | $291.67M | $344.00M |
| Total liabilities | $1.56B | $1.55B | $1.52B | $1.60B | $1.17B | $1.15B | $1.16B | $1.24B |
| Shareholders' equity | -$376.00M | -$291.00M | -$236.00M | -$80.00M | $10.00M | $151.00M | $144.00M | $255.00M |
| Shares outstanding | 101.90M | 98.60M | 98.30M | 96.60M | 96.44M | 96.35M | 93.90M | 92.50M |
| Cash flow statement | ||||||||
| Operating cash flow | -$43.00M | -$97.00M | -$197.00M | -$99.83M | -$91.00M | -$109.00M | -$166.00M | -$79.50M |
| Capital expenditure | $2.00M | $1.00M | $1.00M | $938,000 | $1.00M | $3.00M | $1.00M | $654,000 |
| Free cash flow | -$45.00M | -$98.00M | -$198.00M | -$100.77M | -$92.00M | -$112.00M | -$167.00M | -$80.16M |
| Investing cash flow | $58.00M | $44.00M | -$49.00M | -$72.25M | $117.00M | $71.00M | $120.00M | $102.73M |
| Financing cash flow | $10.00M | — | — | $394.19M | $0 | $83.65M | $157,000 | $3.19M |
| Depreciation & amortization | $9.00M | $8.00M | $8.00M | $8.79M | $8.00M | $9.00M | $9.00M | $9.08M |
| Stock-based compensation | $34.00M | $34.00M | $30,000 | $37.47M | $37.00M | $39.00M | $40,000 | $40.19M |
Free plan shows the latest 8 periods; Pro shows all 55 🔒
· This company does not report gross profit in XBRL.
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.